Coffee consumption and NAFLD: a community based study on 1223 subjects

BMC Research Notes

Volumn 8, Issue 1, 2015, Pages

  Graeter, Tilmann ^a   Niedermayer, Pia C ^a   Mason, Richard A ^b   Oeztuerk, Suemeyra ^a   Haenle, Mark M ^a   Koenig, Wolfgang ^a   Boehm, Bernhard Otto ^a,c,d   Kratzer, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b DEPARTMENT OF VETERANS AFFAIRS   (United States)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^d IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Alanine aminotransferase; Caffeine; Fatty liver; Hepatic steatosis; Population based cross sectional study

Indexed keywords

ALANINE AMINOTRANSFERASE; CAFFEINE; CENTRAL STIMULANT AGENT; COFFEE;

ADOLESCENT; ADULT; AGED; BLOOD; BODY MASS; COFFEE; CROSS-SECTIONAL STUDY; DIAGNOSTIC IMAGING; DRUG EFFECTS; ECHOGRAPHY; FEMALE; HUMAN; LIVER; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; PARTICIPATORY RESEARCH; PATHOLOGY; PROCEDURES; QUESTIONNAIRE; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; BODY MASS INDEX; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; COFFEE; COMMUNITY-BASED PARTICIPATORY RESEARCH; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LIVER; LOGISTIC MODELS; MALE; MIDDLE AGED; NON-ALCOHOLIC FATTY LIVER DISEASE; SURVEYS AND QUESTIONNAIRES; ULTRASONOGRAPHY; YOUNG ADULT;

EID: 84946124678     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-015-1645-3     Document Type: Article

References (27)

1. Sanyal AJ. NASH: a global health problem. Hepatol Res. 2011;41:670-4.
2. Ballestri S, Lonardo A, Bonapace S, et al. Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. World J Gastroenterol. 2014;20:1724-45.
3. Takaki A, Kawai D, Yamamoto K. Molecular mechanisms and new treatment strategies for Non-Alcoholic Steatohepatitis (NASH). Int J Mol Sci. 2014;15:7352-79.
4. Qayyum A, Chen DM, Breiman RS, Westphalen AC, Yeh BM, Jones KD, Lu Y, Coakley FV, Callen PW. Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best? Clin Imaging. 2009;33:110-5.
5. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2012;10:837-58.
6. Torres DM, Harrison SA. Diagnosis and therapy of nonalcoholic steatohepatitis. Gastroenterology. 2008;134:1682-98.
7. Grandison GA, Angulo P. Can NASH be diagnosed, graded, and staged noninvasively? Clin Liver Dis. 2012;16:567-85.
8. Saab S, Mallam D, Cox GA 2nd, et al. Impact of coffee on liver diseases: a systematic review. Liver Int. 2014;34:495-504.
9. Cano-Marquina A, Tarín JJ, Cano A. The impact of coffee on health. Maturitas. 2013;75:7-21.
10. Higdon JV, Frei B. Coffee and health: a review of recent human research. Crit Rev Food Sci Nutr. 2006;46:101-23.
11. Chen S, Teoh NC, Chitturi S, et al. Coffee and non-alcoholic fatty liver disease: brewing evidence for hepatoprotection? J Gastroenterol Hepatol. 2014;29:435-41.
12. Modi AA, Feld JJ, Park Y, et al. Increased caffeine consumption is associated with reduced hepatic fibrosis. Hepatology. 2010;51:201-9.
13. Molloy JW, Calcagno CJ, Williams CD. Association of coffee and caffeine consumption with fatty liver disease, nonalcoholic steatohepatitis, and degree of hepatic fibrosis. Hepatology. 2012;55:429-36.
14. Bambha K, Wilson LA, Unalp A, et al. Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis. Liver Int. 2014;34:1250-8.
15. Catalano D, Martines GF, Tonzuso A, et al. Protective role of coffee in non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2010;55:3200-6.
16. Birerdinc A, Stepanova M, Pawloski L, et al. Caffeine is protective in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2012;35:76-82.
17. Jang ES, Jeong SH, Hwang SH, et al. Effects of coffee, smoking, and alcohol on liver function tests: a comprehensive cross-sectional study. BMC Gastroenterol. 2012;12:145.
18. Muriel P, Arauz J. Coffee and liver diseases. Fitoterapia. 2010;81:297-305.
19. Ruhl CE, Everhart JE. Coffee and caffeine consumption reduce the risk of elevated serum alanin aminotransferase activity in the United States. Gastroenterology. 2005;128:24-32.
20. Ong A, Wong VW, Wong GL, Chan HL. The effect of caffeine and alcohol consumption on liver fibrosis - a study of 1045 Asian hepatitis B patients using transient elastography. Liver Int. 2011;31:1047-53.
21. Jang ES, Jeong SH, Lee SH, et al. The effect of coffee consumption on the development of hepatocellular carcinoma in hepatitis B virus endemic area. Liver Int. 2013;33:1092-9.
22. Haenle MM, Brockmann SO, Kron M, et al. Overweight, physical activity, tobacco and alcohol consumption in a cross-sectional random sample of German adults. BMC Public Health. 2006;6:233.
23. Charatcharoenwitthaya P, Lindor KD. Role of radiologic modalities in the management of non-alcoholic steatohepatitis. Clin Liver Dis. 2007;11:37-54.
24. Kratzer W, Akinli AS, Bommer M, et al. Prevalence and risk factors of focal sparing in hepatic steatosis. Ultraschall Med. 2010;31:37-42.
25. Zhang H, Jiang YF, He SM, et al. Etiology and prevalence of abnormal serum alanine aminotransferase levels in a general population in Northeast China. Chin Med J (Engl). 2011;124:2661-8.
26. Gutiérrez-Grobe Y, Chávez-Tapia N, Sánchez-Valle V, et al. High coffee intake is associated with lower grade nonalcoholic fatty liver disease: the role of peripheral antioxidant activity. Ann Hepatol. 2012;11:350-5.
27. Yamashita K, Yatsuya H, Muramatsu T, et al. Association of coffee consumption with serum adiponectin, leptin, inflammation and metaboli markers in Japanese workers: a cross-sectional study. Nutr Diabetes. 2012;2:e33.